| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20058177 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20041182 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058236 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058541 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058450 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058625 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058973 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44005801 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44030180 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44022244 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C2 |
|---|---|
| DrugBank ID | DB01023 |
| Drug Name | Felodipine |
| Target ID | BE0000668 |
| UniProt ID | P08235 |
| Regulation Type | antagonist |
| PubMed IDs | 18250364 |
| Citations | Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. |
| Groups | Approved; Investigational |
| Direct Classification | Dihydropyridinecarboxylic acids and derivatives |
| SMILES | CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC |
| Pathways | Felodipine Metabolism Pathway; Felodipine Action Pathway |
| PharmGKB | PA449591 |
| ChEMBL | CHEMBL1480 |
